A phase I study (NCT02454634) found that the IDH1-vac vaccine was well-tolerated and produced immune responses in 93.3% of patients with IDH1(R132H)-positive astrocytomas. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).